Shopping Cart
- Remove All
- Your shopping cart is currently empty
JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $38 | In Stock | |
10 mg | $59 | In Stock | |
25 mg | $118 | In Stock | |
50 mg | $197 | In Stock | |
100 mg | $296 | In Stock | |
200 mg | $419 | In Stock |
Description | JZP-361 is a specific MAGL inhibitor with IC50s of 46 nM, 7.24 μM, and 1.79 μM for human recombinant MAGL, human recombinant FAAH, and human hABHD6. JZP-361 displays anti-histaminergic activities. JZP-361 can be used in studies about asthma. |
Targets&IC50 | ABHD6 (human):1.79 μM, FAAH (human):7.24 μM, MAGL (human):46 nM, H1 receptor:6.81 (pA2) |
In vitro | JZP-361 shows the affinity of H1 antagonistic with a pA2 of 6.81). JZP-361(≤10 μM) does not show cannabinoid receptor activity. JZP-361 displays favorable interactions within the important hydrogen-bonding of the carbonyl oxygen to the oxyanion hole[1]. |
Alias | JZP361, JZP 361 |
Molecular Weight | 405.88 |
Formula | C22H20ClN5O |
Cas No. | 1680193-80-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | Ethanol: 36.5 mg/mL (90.0 mM) DMSO: 1 mg/ml, Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
Ethanol
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.